Mohamed Alorabi, Lecturer of Clinical Oncology at Faculty of Medicine, Ain Shams University, Egypt and Consultant Medical Oncologist and Head of Department at Abha Intel. Private Hospital, shared a post on LinkedIn:
“Common practice worth rethinking in glioblastoma.
Routine PPI prophylaxis to prevent steroid-induced gastritis is common practice in patients with newly diagnosed glioblastoma.
However, a large JAMA Network Open (Nov 2025) individual patient data meta-analysis (Le Rhun et al., n=2,981) found that PPI use was associated with worse PFS and OS, independent of MGMT status, steroid use, and other key prognostic factors.
Notably, this signal was limited to potent ALDH1A1-activating PPIs, and not seen with other antacids.
Take-home: Even supportive medications matter. When possible, avoid routine PPIs in glioblastoma and consider alternative gastric protection.”
More posts on OncoDaily.